Lysosome and HER3 (ErbB3) selective anticancer agent Kahalalide F: Semisynthetic modifications and antifungal lead-exploration studies

Journal of Medicinal Chemistry

Volumn 50, Issue 18, 2007, Pages 4340-4350

  Shilabin, Abbas Gholipour ^a   Kasanah, Noer ^a   Wedge, David E ^b   Hamann, Mark T ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMINE; AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; AZOXYSTROBIN; CAPTAN; CIPROFLOXACIN; EPIDERMAL GROWTH FACTOR RECEPTOR 3; KAHALALIDE F; KAHALALIDE G; ORNITHINE; THREONINE; UNCLASSIFIED DRUG;

ACETYLATION; ALKYLATION; ANTIBACTERIAL ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIMALARIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPERGILLUS FUMIGATUS; CANCER CELL CULTURE; CANDIDA ALBICANS; CARBON NUCLEAR MAGNETIC RESONANCE; CRYPTOCOCCUS NEOFORMANS; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SELECTIVITY; ESCHERICHIA COLI; FUNGAL STRAIN; FUSARIUM; FUSARIUM OXYSPORUM; FUSARIUM PROLIFERATUM; FUSARIUM SOLANI; HUMAN; HUMAN CELL; IN VITRO STUDY; LEISHMANIA DONOVANI; LYSOSOME; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MYCOBACTERIUM INTRACELLULARE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; OXIDATION; PLASMODIUM FALCIPARUM; PROTON NUCLEAR MAGNETIC RESONANCE; PSEUDOMONAS AERUGINOSA; REDUCTION; STRUCTURE ACTIVITY RELATION;

ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; ANTIPARASITIC AGENTS; CELL LINE, TUMOR; DEPSIPEPTIDES; DRUG SCREENING ASSAYS, ANTITUMOR; FUSARIUM; HUMANS; LYSOSOMES; MICROBIOLOGICAL TECHNIQUES; MYCOBACTERIUM TUBERCULOSIS; OPPORTUNISTIC INFECTIONS; PARASITIC SENSITIVITY TESTS; RECEPTOR, ERBB-3; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34548502668     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm061288r     Document Type: Article

References (44)

1. Hamann, M. T.; Scheuer, P. J. Kahalalide F: a bioactive depsipeptide from the sacoglossan mollusk Elysia rufescens and the green alga Bryopsis sp. J. Am. Chem. Soc. 1993, 115, 5825-5826.
2. Hamann, M. T.; Otto, C. S.; Scheuer, P. J.; Dunbar, D. C. Kahalalides: bioactive peptides from a marine mollusk Elysia rufescens and its algal diet Bryopsis sp. J. Org. Chem. 1996, 61, 6594-6600.
3. Goetz, G.; Nakao, Y.; Scheuer, P. J. Two acyclic kahalalides from the sacoglossan mollusk Elysia rufescens. J. Nat. Prod. 1997, 60, 562-567.
4. Horgen, F. D.; de los Santos, D. B.; Goetz, G.; Sakamoto, B.; Kan, Y.; Nagai, H.; Scheuer, P. J. A new depsipeptide from the sacoglossan mollusk Elysia ornata and the green alga Bryopsis species. J. Nat. Prod. 2000, 63, 152-154.
5. Hill, R. T.; Hamann, M. T.; Enticknap, J.; Rao, K. V. Kahalalide-producing bacteria. PCT Int. Appl. WO 2005/042720, 2005.
6. Dmitrenok, A.; Iwashita, T.; Nakajima, T.; Sakamoto, B.; Namikoshi, M.; Nagai, H. New cyclic depsipeptides from the green alga Bryopsis species; application of a carboxypeptidase hydrolysis reaction to the structure determination. Tetrahedron 2006, 62, 1301-1308.
7. Ashour, M.; Edrada, R.; Ebel, R.; Wray, V.; Wätjen, W.; Padmakumar, K.; Müller, W. E. G.; Lin, W. H.; Proksch, P. Kahalalide derivatives from the Indian sacoglossan mollusk Elysia grandifolia. J. Nat. Prod. 2006, 69, 1547-1553.
8. Tilvi, S.; Naik C. G. Tandem mass spectroscopy of kahalalides: identification of two new cyclic depsipeptides, kahalalide R and S from Elysia grandifolia. J. Mass Spectrom. 2006, 42, 70-80.
9. Bonnard, I.; Manzanares, I.; Rinehart, K. L. Stereochemistry of kahalalide F. J. Nat. Prod. 2003, 66, 1466-1470.
10. Lopez-Macia, A.; Jimenez, J. C.; Royo, M.; Giralt, E.; Albericio, F. Synthesis and structure determination of kahalalide F. J. Am. Chem. Soc. 2001, 123, 11398-11401.
11. Rademaker, J. M.; Horenblas, S.; Meinhardt, W.; Stokvis, E.; de Reijke, T. M.; Jimeno, J. M.; Lopez-Lazaro, S.; Lopez, Martin, J. A.; Beijnen, J. H.; Schellens, J. H. M. Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer. Clin. Cancer Res. 2005, 11, 1854-1862.
12. Hamann, M. T. Technology evaluation: kahalalide F (PharmaMar). Curr. Opin. Mol. Ther. 2004, 6, 657-665.
13. PharmaMar Biopharmaceutical Co. (www.pharmamar.com). Presented at the 31st European Society for Medical Oncology Congress (ESMO), Istanbul, Turkey, September 29 through October 3, 2006.
14. Garcia-Rocha, M.; Bonay, P.; Avila, J. The antitumoral compound kahalalide facts on cell lysosomes. Cancer Lett. 1996, 99, 43-50.
15. Suarez, Y.; Gonzalez, L.; Cuadrado, A.; Berciano, M.; Lafarga, M.; Munoz, A. Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells. Mol. Cancer Ther. 2003, 2, 863-872.
16. Faircloth, G. T.; Smith, B.; Grant, W.; Jimeno, J. M.; Garcia-Gravalos, L.; Scotto, K.; Shtil, A. Selective antitumor activity of kahalalide F, a marine-derived cyclic depsipeptide. Proc. Am. Assoc. Cancer Res. 2001, 42, 213.
17. Janmaat, M.; Rodriguez, J.; Jimeno, J.; Kruyt, F.; Giaccone, G. Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling. Mol. Pharmacol. 2005, 68, 502-510.
18. Jimeno, J.; Aracil, M.; Tercero, J. Adding pharmacogenomics to the development of new marine-derived anticancer agents. J. Transl. Med. 2006, 4, 1-9.
19. (a) Jarvis, L. M. Battling breast cancer by targeting multiple HER-family receptors, small-molecule drugs could fill the therapeutic gaps left by Herceptin. Chem. Eng. News 2006, 84 (32), 21-27.
20. (b) Holbro, T.; Beerli, R. R.; Maurer, F.; Koziczak, M.; Barbas, C. F.; Hynes, N. E. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. U.S.A. 2003, 100 (15), 8933-8938.
21. Albericio, P. F.; Giralt, L. E.; Jiménez, G. J.-C.; Lopez, M. A.; Manzanares, I.; Rodrigues, I.; Royo, E. M. Kahalalide compounds. PCT Int. Appl. WO 01/58934, 2001.
22. Albericio, P. F.; Fernandez, D. A.; Giralt, L. E.; Gracia, C. C.; Lopez, R. P.; Varon, C. S.; Cuevas, M. C.; Lopez, M. A.; Francesca, S. A.; Jiménez, G. J.-C.; Royo, E. M. New antitumoral compounds. PCT Int. Appl. WO 2005/023846, 2005.
23. Gracia, C.; Isidro-Llobet, A.; Cruz, L. J.; Acosta, G. A.; Alvarez, M.; Cuevas, C.; Giralt, E.; Albericio, F. Convergent approaches for the synthesis of the antitumoral peptide, kahalalide F. Study of orthogonal protecting groups. J. Org. Chem. 2006, 71, 7196-7204.
24. Faircloth, G. T.; Elices, M.; Sasak, H.; Aviles Marin, P. M.; Cuevas Marchante, M. D. C. Preparation of kahalalide antitumoral compounds. PCT Int. Appl. WO 2004/035613, 2004.
25. Peng, J.; Shen, X.; El Sayed, K. A.; Dunbar, D. C.; Perry, T. L.; Wilkins, S. P.; Hamann, M. T.; Bobzin, S.; Huesing, J.; Camp, R.; Prinsen, M.; Krupa, D.; Wideman, M. A. Marine natural products as prototype agrochemical agents. J. Agric. Food Chem. 2003, 51, 2246-2252.
26. Scheuer, P. J.; Hamann, M. T.; Gravalos, D. G. Cytotoxic and antimicrobial activities of kahalalide F from Elysia rufescens. U.S. Patent 6274551, 2001.
27. (a) Patai, S. The Chemistry of Amino, Nitroso, Nitro and Related Groups; Wiley: New York, 1996.
28. (b) Salvatore, R. N.; Yoon, C. H.; Jung, K. W. Synthesis of secondary amines. Tetrahedron 2001, 57, 7785-7811.
29. (c) Insaf, S. S.; Witiak, D. T. Facile non-racemizing route for the N-alkylation of hindered secondary amines. Synthesis 1999, 3, 435.
30. Arikan, S.; Rex, J. H. New agents for the treatment of systemic fungal infections - current status. Expert Opin. Emerging Drugs 2002, 7, 3-32.
31. De Lucca, A. J. Antifungal peptides: potential candidates for the treatment of fungal infections. Expert Opin. Invest. Drugs 2000, 9, 273-299.
32. Hancock, R. E. W.; Chapple, D. S. Peptide antibiotics. Antimicrob. Agents Chemother. 1999, 43, 1317-1323.
33. Vanden Bossche, H. Echinocandins, an update. Expert Opin. Ther. Pat. 2002, 12, 151-167.
34. Martinez-Pascual, R.; Vinas-Bravo, O.; Meza-reyes, S.; Iglesias-Arteaga, M. A.; Sandoval-Ramirez, J. A fast and convenient procedure for the acetylation of alcohols. Synth. Commun. 2004, 34, 4591-4596.
35. Meyer, S. D.; Schreiber, S. L. Acceleration of the Dess-Martin oxidation by water. J. Org. Chem. 1994, 59, 7549-7552.
36. (a) Borch, R. F.; Bernstein, M. D.; Durst, H. D. Cyanohydridoborate anion as a selective reducing agent. J. Am. Chem. Soc. 1971, 93, 2897-2904.
37. (b) Bomann, M. D.; Guch, I. C.; DiMare, M. A mild, pyridine-borane-based reductive amination protocol. J. Org. Chem. 1996, 60, 5995-5996.
38. (c) Szardenings, A. K.; Burkoth, T. S.; Look, G. C.; Campbell, D. A. A reductive alkylation procedure applicable to both solution- and solid-phase syntheses of secondary amines. J. Org. Chem. 1996, 61, 6720-6722.
39. (a) Gribble, G. W.; Ferguson, D. C. Reactions of sodium borohydride in acidic media. Selective reduction of aldehydes with sodium triacetoxyborohydride. J. Chem. Soc., Chem. Commun. 1975, 535-536.
40. (b) Nutaitis, C. F.; Gribble, G. W. Chemoselective reduction of aldehydes with tetra-n-butylammonium triacetoxyborohydride. Tetrahedron Lett. 1983, 24, 4287.
41. (c) Gribble, G. W. Encyclopedia of Reagents for Organic Synthesis; Paquette, L. A., Ed.; John Wiley and Sons: New York, 1995; Vol. 7, p 4649.
42. Sandler, J. S.; Fenical, W.; Gulledge, B. M.; Chamberlin, A. R.; La Clair, J. J. Fluorescent profiling of natural product producers. J. Am. Chem. Soc. 2005, 127, 9320-9321.
43. Wedge, D. E.; Kuhajek, J. M. A microbioassay for fungicide discovery. SAAS Bull. Biochem. Biotechnol. 1998, 11, 1-7.
44. Collins, L.; Franzblau, S. G. Microplate Alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob. Agents Chemother. 1997, 41, 1004-1009.